Literature DB >> 27834957

PIN1 in breast development and cancer: a clinical perspective.

Alessandra Rustighi1, Alessandro Zannini1,2, Elena Campaner1,2, Yari Ciani1, Silvano Piazza1,3, Giannino Del Sal1,2.   

Abstract

Mammary gland development, various stages of mammary tumorigenesis and breast cancer progression have the peptidyl-prolyl cis/trans isomerase PIN1 at their centerpiece, in virtue of the ability of this unique enzyme to fine-tune the dynamic crosstalk between multiple molecular pathways. PIN1 exerts its action by inducing conformational and functional changes on key cellular proteins, following proline-directed phosphorylation. Through this post-phosphorylation signal transduction mechanism, PIN1 controls the extent and direction of the cellular response to a variety of inputs, in physiology and disease. This review discusses PIN1's roles in normal mammary development and cancerous progression, as well as the clinical impact of targeting this enzyme in breast cancer patients.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27834957      PMCID： PMC5299711          DOI： 10.1038/cdd.2016.122

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN： 1350-9047            Impact factor:   15.828


  76 in total

1.  BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression.

Authors:  T K MacLachlan; K Somasundaram; M Sgagias; Y Shifman; R J Muschel; K H Cowan; W S El-Deiry
Journal:  J Biol Chem       Date:  2000-01-28       Impact factor: 5.157

2.  Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1.

Authors:  G M Wulf; A Ryo; G G Wulf; S W Lee; T Niu; V Petkova; K P Lu
Journal:  EMBO J       Date:  2001-07-02       Impact factor: 11.598

3.  A Pin1/mutant p53 axis promotes aggressiveness in breast cancer.

Authors:  Javier E Girardini; Marco Napoli; Silvano Piazza; Alessandra Rustighi; Carolina Marotta; Enrico Radaelli; Valeria Capaci; Lee Jordan; Phil Quinlan; Alastair Thompson; Miguel Mano; Antonio Rosato; Tim Crook; Eugenio Scanziani; Anthony R Means; Guillermina Lozano; Claudio Schneider; Giannino Del Sal
Journal:  Cancer Cell       Date:  2011-07-12       Impact factor: 31.743

Review 4.  Prolyl isomerases in gene transcription.

Authors:  Steven D Hanes
Journal:  Biochim Biophys Acta       Date:  2014-10-31

5.  Pin1 inhibitors: Pitfalls, progress and cellular pharmacology.

Authors:  Jonathan D Moore; Andrew Potter
Journal:  Bioorg Med Chem Lett       Date:  2013-06-06       Impact factor: 2.823

6.  Mice lacking Pin1 develop normally, but are defective in entering cell cycle from G(0) arrest.

Authors:  F Fujimori; K Takahashi; C Uchida; T Uchida
Journal:  Biochem Biophys Res Commun       Date:  1999-11-30       Impact factor: 3.575

Review 7.  The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.

Authors:  Aleix Prat; José Baselga
Journal:  Nat Clin Pract Oncol       Date:  2008-07-08

Review 8.  Targeting metastasis.

Authors:  Patricia S Steeg
Journal:  Nat Rev Cancer       Date:  2016-04       Impact factor: 60.716

9.  The Rab2A GTPase promotes breast cancer stem cells and tumorigenesis via Erk signaling activation.

Authors:  Man-Li Luo; Chang Gong; Chun-Hau Chen; Hai Hu; Pengyu Huang; Min Zheng; Yandan Yao; Shuo Wei; Gerburg Wulf; Judy Lieberman; Xiao Zhen Zhou; Erwei Song; Kun Ping Lu
Journal:  Cell Rep       Date:  2015-03-26       Impact factor: 9.423

10.  The prolyl isomerase pin1 regulates mRNA levels of genes with short half-lives by targeting specific RNA binding proteins.

Authors:  Nithya Krishnan; Mark A Titus; Roopa Thapar
Journal:  PLoS One       Date:  2014-01-09       Impact factor: 3.240
View more
  14 in total

Review 1.  Functional analyses of major cancer-related signaling pathways in Alzheimer's disease etiology.

Authors:  Jianping Guo; Ji Cheng; Brian J North; Wenyi Wei
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-07-08       Impact factor: 10.680

2.  Inhibition of peptidyl-prolyl isomerase (PIN1) and BRAF signaling to target melanoma.

Authors:  Christina Braun; Nadja Schneider; Dehua Pei; Anja Bosserhoff; Silke Kuphal
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

3.  Peptidyl-prolyl cis/trans isomerase Pin1 regulates withaferin A-mediated cell cycle arrest in human breast cancer cells.

Authors:  Suman K Samanta; Joomin Lee; Eun-Ryeong Hahm; Shivendra V Singh
Journal:  Mol Carcinog       Date:  2018-04-16       Impact factor: 4.784

4.  Inhibition of CDK-mediated Smad3 phosphorylation reduces the Pin1-Smad3 interaction and aggressiveness of triple negative breast cancer cells.

Authors:  Alexandra L Thomas; Hanne Lind; Angela Hong; Danijela Dokic; Kailey Oppat; Elana Rosenthal; Amina Guo; Aaron Thomas; Randala Hamden; Jacqueline S Jeruss
Journal:  Cell Cycle       Date:  2017-07-05       Impact factor: 4.534

5.  A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action.

Authors:  Elena Campaner; Alessandra Rustighi; Alessandro Zannini; Alberto Cristiani; Silvano Piazza; Yari Ciani; Ori Kalid; Gali Golan; Erkan Baloglu; Sharon Shacham; Barbara Valsasina; Ulisse Cucchi; Agnese Chiara Pippione; Marco Lucio Lolli; Barbara Giabbai; Paola Storici; Paolo Carloni; Giulia Rossetti; Federica Benvenuti; Ezia Bello; Maurizio D'Incalci; Elisa Cappuzzello; Antonio Rosato; Giannino Del Sal
Journal:  Nat Commun       Date:  2017-06-09       Impact factor: 14.919

6.  Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways.

Authors:  Xiaolan Lian; Yu-Min Lin; Shingo Kozono; Megan K Herbert; Xin Li; Xiaohong Yuan; Jiangrui Guo; Yafei Guo; Min Tang; Jia Lin; Yiping Huang; Bixin Wang; Chenxi Qiu; Cheng-Yu Tsai; Jane Xie; Ziang Jeff Gao; Yong Wu; Hekun Liu; Xiao Zhen Zhou; Kun Ping Lu; Yuanzhong Chen
Journal:  J Hematol Oncol       Date:  2018-05-30       Impact factor: 17.388

7.  Cytoplasmic Pin1 expression is increased in human cutaneous melanoma and predicts poor prognosis.

Authors:  Xin Chen; Xiaosong Liu; Bin Deng; Magdalena Martinka; Youwen Zhou; Xiaopeng Lan; Yabin Cheng
Journal:  Sci Rep       Date:  2018-11-15       Impact factor: 4.379

8.  Predictive Value of Pin1 in Cervical Low-Grade Squamous Intraepithelial Lesions and Inhibition of Pin1 Exerts Potent Anticancer Activity against Human Cervical Cancer.

Authors:  Yan-Tong Guo; Yan Lu; Yi-Yang Jia; Hui-Nan Qu; Da Qi; Xin-Qi Wang; Pei-Ye Song; Xiang-Shu Jin; Wen-Hong Xu; Yuan Dong; Ying-Ying Liang; Cheng-Shi Quan
Journal:  Aging Dis       Date:  2020-02-01       Impact factor: 6.745

Review 9.  Mini Review: Opposing Pathologies in Cancer and Alzheimer's Disease: Does the PI3K/Akt Pathway Provide Clues?

Authors:  Rachel M Barker; Jeff M P Holly; Kalina M Biernacka; Shelley J Allen-Birt; Claire M Perks
Journal:  Front Endocrinol (Lausanne)       Date:  2020-06-23       Impact factor: 5.555

10.  Pin1 Is Involved in HDAC6-mediated Cancer Cell Motility.

Authors:  Hsiang-Hao Chuang; Ming-Shyan Huang; Pei-Hui Wang; Yu-Peng Liu; Michael Hsiao; Chih-Jen Yang
Journal:  Int J Med Sci       Date:  2018-10-20       Impact factor: 3.738
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.